Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Question

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Dec 10, 2023 7:25pm

136 Views

Post# 35777145

RE:RE:RE:RE:RE:RE:RE:RE:Question

Hi Azzak... well, it got the nod from the FDA, and more approvals to come which was a massive deal. Of course I was dissapointed that stock sold off on the day, but I was in months ago, so am still comfortably in the money. Bluebird bio was also approved sameday for their gene editing therapy, and the stock was down 40%, so some of the CRSP downturn could have been related.

Stll, the positive is that they now have a approval, and have demonstated that this approach works, so it opens the doors for this kind of therapy in other areas. With their partnership with Vertex, cash in the bank and an enviable pipeline, I'm very happy holding.

Did you trade any ?

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing